36 results on '"Zheng, Qiufan"'
Search Results
2. Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
- Author
-
Jiang, Kuikui, Zhou, Danyang, Xu, Fei, Xia, Wen, Zheng, Qiufan, Lu, Qianyi, Luo, Rongzhen, Hong, Ruoxi, and Wang, Shusen
- Published
- 2023
- Full Text
- View/download PDF
3. Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study
- Author
-
Zheng, Qiufan, Luo, Hanjia, Xia, Wen, Lu, Qianyi, Jiang, Kuikui, Hong, Ruoxi, Xu, Fei, and Wang, Shusen
- Published
- 2022
- Full Text
- View/download PDF
4. Nail pigmentation induced by chemotherapy: an observational study of patients with early-stage breast cancer
- Author
-
Jiang, Kuikui, Shi, Simei, Lin, Qiulian, Sun, Peng, Zhang, Luan, Yuan, Zhongyu, Hong, Ruoxi, Shi, Yanxia, Liu, Xia, Zhang, Jingmin, Huang, Jiajia, Bi, Xiwen, Xia, Wen, Lu, Qianyi, Zheng, Qiufan, Wang, Shusen, and Xu, Fei
- Published
- 2022
- Full Text
- View/download PDF
5. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
- Author
-
Jiang, Kuikui, Hong, Ruoxi, Xia, Wen, Lu, Qianyi, Li, Liang, Huang, Jianhao, Shi, Yanxia, Yuan, Zhongyu, Zheng, Qiufan, An, Xin, Xue, Cong, Huang, Jiajia, Bi, Xiwen, Chen, Meiting, Zhang, Jingmin, Xu, Fei, and Wang, Shusen
- Subjects
HER2 positive breast cancer ,METASTATIC breast cancer ,EPIDERMAL growth factor receptors ,VINORELBINE ,LEUKOCYTE count - Abstract
Purpose This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice. Materials and Methods This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety. Results A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%). Conclusion Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. CPSF4 promotes triple negative breast cancer metastasis by upregulating MDM4
- Author
-
Lee, Kaping, Zheng, Qiufan, Lu, Qianyi, Xu, Fei, Qin, Ge, Zhai, Qinglian, Hong, Ruoxi, Chen, Miao, Deng, Wuguo, and Wang, Shusen
- Published
- 2021
- Full Text
- View/download PDF
7. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
- Author
-
Zheng, Qiufan, Hong, Shaodong, Huang, Yan, Zhao, Hongyun, Yang, Yunpeng, Hou, Xue, Zhao, Yuanyuan, Ma, Yuxiang, Zhou, Ting, Zhang, Yaxiong, Fang, Wenfeng, and Zhang, Li
- Published
- 2020
- Full Text
- View/download PDF
8. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing
- Author
-
Zhang, Yaxiong, Chang, Lianpeng, Yang, Yunpeng, Fang, Wenfeng, Guan, Yanfang, Wu, Aiwei, Hong, Shaodong, Zhou, Huaqiang, Chen, Gang, Chen, Xi, Zhao, Shen, Zheng, Qiufan, Pan, Hui, Zhang, Lanjun, Long, Hao, Yang, Haoxian, Wang, Xin, Wen, Zhesheng, Wang, Junye, Yang, Hong, Xia, Xuefeng, Zhao, Yuanyuan, Hou, Xue, Ma, Yuxiang, Zhou, Ting, Zhang, Zhonghan, Zhan, Jianhua, Huang, Yan, Zhao, Hongyun, Zhou, Ningning, Yi, Xin, and Zhang, Li
- Published
- 2019
- Full Text
- View/download PDF
9. The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence.
- Author
-
Zhou, Danyang, Li, Mei, Xu, Fei, Zheng, Qiufan, Lu, Qianyi, Hong, Ruoxi, and Wang, Shusen
- Subjects
EPIDERMAL growth factor receptors ,BREAST cancer ,CANCER patients - Abstract
To assess the prognostic significance of skin involvement in breast cancer patients with chest wall recurrence (CWR). We retrospectively analyzed the clinicopathological data of breast cancer patients with CWR who were diagnosed pathologically between January 2000 and April 2020. Disease-free survival (DFS) was the time from radical resection for CWR to disease recurrence. Progression-free survival (PFS) was defined as the time from the diagnosis of locally unresectable CWR to the first sign of disease progression. Persistent chest wall progression was defined as three consecutive chest wall progressions with no distant organ involvement. A total of 476 patients with CWR were included in this study. Skin involvement was confirmed in 345 patients. Skin involvement was significantly correlated with a high T stage (p = 0.003), more positive nodes at initial examination (p < 0.001) and lymphovascular invasion (p < 0.001). Kaplan–Meier analysis showed that skin involvement was a predictor of shorter DFS (p < 0.001), including both local disease progression (p < 0.001) and distant disease progression (p = 0.022). Multivariate analysis showed that skin involvement was an independent biomarker for DFS (p = 0.043). Patients with skin involvement were more likely to experience persistent chest wall progression (p = 0.040). After eliminating the potential deviation caused by an insufficient follow-up time, persistent chest wall progression was more likely to be associated with a high N stage (p = 0.002), negative progesterone receptor (PR; p = 0.001) and positive human epidermal growth factor receptor 2 (HER2; p = 0.046) of the primary site, and negative oestrogen receptor (ER; p = 0.027) and PR (p = 0.013) of the chest wall lesion and skin involvement (p = 0.020). Skin involvement was a predictor of poor disease control in patients with CWR and was closely related to persistent chest wall progression. We stratified the prognosis of individualized treatment for breast cancer patients with CWR to provide new insights into the biological behaviours of the disease. Skin involvement is a predictor of poor local disease control in breast cancer patients with CWR and a factor contributing to persistent chest wall progression after CWR. We stratified the prognosis of individualized treatment for breast cancer patients with CWR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma
- Author
-
Hong, Shaodong, Liu, Dongbing, Luo, Shuzhen, Fang, Wenfeng, Zhan, Jianhua, Fu, Sha, Zhang, Yaxiong, Wu, Xuan, Zhou, Huaqiang, Chen, Xi, Chen, Gang, Zhang, Zhonghan, Zheng, Qiufan, Li, Xiaobo, Chen, Jinghao, Liu, Xingmin, Lei, Mengyue, Ye, Chen, Wang, Jian, Yang, Huanming, Xu, Xun, Zhu, Shida, Yang, Yunpeng, Zhao, Yuanyuan, Zhou, Ningning, Zhao, Hongyun, Huang, Yan, Zhang, Lanjun, Wu, Kui, and Zhang, Li
- Published
- 2019
- Full Text
- View/download PDF
11. Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis
- Author
-
Zheng, Qiufan, Xia, Wen, Lu, Qianyi, Hong, Ruoxi, Qin, Ge, Xu, Fei, Qin, Tao, Shi, Yanxia, Yuan, Zhongyu, and Wang, Shusen
- Published
- 2016
- Full Text
- View/download PDF
12. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?—Analysis of genetic and clinical features from a single cancer center database.
- Author
-
Ni, Mengqian, Wang, Fang, Yang, Anli, Shao, Qiong, Xue, Cong, Xia, Wen, Xu, Fei, Lin, Xi, Huang, Jiajia, Bi, Xiwen, Hong, Ruoxi, Chen, Meiting, Zheng, Qiufan, Jiang, Kuikui, Xie, Xinhua, Tang, Jun, Wang, Xi, Yuan, Zhongyu, Wang, Shusen, and Shi, Yanxia
- Subjects
GENETIC testing ,CHINESE people ,BRCA genes ,BREAST cancer ,DATABASES ,HEREDITARY nonpolyposis colorectal cancer - Abstract
Background: Genetic testing plays an important role in guiding screening, diagnosis, and precision treatment of breast cancer (BC). However, the appropriate genetic testing criteria remain controversial. The current study aims to facilitate the development of suitable strategies by analyzing the germline mutational profiles and clinicopathological features of large‐scale Chinese BC patients. Methods: BC patients who had undergone genetic testing at the Sun Yat‐sen University Cancer Center (SYSUCC) from September 2014 to March 2022 were retrospectively reviewed. Different screening criteria were applied and compared in the population cohort. Results: A total of 1035 BC patients were enrolled, 237 pathogenic or likely pathogenic variants (P/LPV) were identified in 235 patients, including 41 out of 203 (19.6%) patients tested only for BRCA1/2 genes, and 194 out of 832 (23.3%) received 21 genes panel testing. Among the 235 P/LPV carriers, 222 (94.5%) met the NCCN high‐risk criteria, and 13 (5.5%) did not. While using Desai's criteria of testing, all females diagnosed with BC by 60 years and NCCN criteria for older patients, 234 (99.6%) met the high‐risk standard, and only one did not. The 21 genes panel testing identified 4.9% of non‐BRCA P/LPVs and a significantly high rate of variants of uncertain significance (VUSs) (33.9%). The most common non‐BRCA P/LPVs were PALB2 (11, 1.3%), TP53 (10, 1.2%), PTEN (3, 0.4%), CHEK2 (3, 0.4%), ATM (3, 0.4%), BARD1 (3, 0.4%), and RAD51C (2, 0.2%). Compared with BRCA1/2 P/LPVs, non‐BRCA P/LPVs showed a significantly low incidence of NCCN criteria listed family history, second primary cancer, and different molecular subtypes. Conclusions: Desai's criteria might be a more appropriate genetic testing strategy for Chinese BC patients. Panel testing could identify more non‐BRCA P/LPVs than BRCA1/2 testing alone. Compared with BRCA1/2 P/LPVs, non‐BRCA P/LPVs exhibited different personal and family histories of cancer and molecular subtype distributions. The optimal genetic testing strategy for BC still needs to be investigated with larger continuous population studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer
- Author
-
An, Xin, Xu, Fei, Luo, Rongzhen, Zheng, Qiufan, Lu, Jiabin, Yang, Yanhua, Qin, Tao, Yuan, Zhongyu, Shi, Yanxia, Jiang, Wenqi, and Wang, Shusen
- Published
- 2018
- Full Text
- View/download PDF
14. Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors.
- Author
-
Jiang, Kuikui, Zhou, Danyang, Hong, Ruoxi, Lu, Qianyi, Xu, Fei, Xia, Wen, Zheng, Qiufan, and Wang, Shusen
- Subjects
TRASTUZUMAB ,HER2 positive breast cancer ,METASTATIC breast cancer ,PHYSICIANS ,CANCER patients ,EPIDERMAL growth factor receptors - Abstract
Background: The Advanced Breast Cancer Alliance conducted a nationwide investigation to understand the current situation of the diagnosis and treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) patients. Methods: In 2019, electronic questionnaires including basic information about respondents, characteristics of patients, and the present status of diagnosis and treatment were sent to 495 doctors from 203 medical centers covering 28 provinces. Results: The factors that influenced treatment plans included the disease process, the performance status, and the economic status of patients. Regimens and response to neoadjuvant/adjuvant chemotherapy were important factors in the decision of the first-line treatment. Overall, 54% of doctors retained trastuzumab and replaced chemotherapy drugs in second-line treatment regimens for patients with progression-free survival (PFS) ≥ 6 months in the first-line setting, while 52% of participants chose pyrotinib plus capecitabine for patients with PFS < 6 months. Economic factors played an important role in doctors' decision-making and the varying treatment options for respondents in first-tier, second-tier, and other cities. Conclusions: This large-scale survey regarding the diagnosis and treatment of HER2-positive MBC patients revealed that clinical decisions made by Chinese doctors followed the guidelines, but their choices were constrained by economic factors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study.
- Author
-
Ma, Yuyu, Duan, Fangfang, Zhuang, Yue, Song, Chenge, Huang, Jiajia, Xia, Wen, Hong, Ruoxi, Zheng, Qiufan, Wang, Shusen, Shi, Yanxia, Xu, Fei, Yuan, Zhongyu, and Bi, Xiwen
- Subjects
BREAST tumor treatment ,BREAST cancer prognosis ,THERAPEUTIC use of antineoplastic agents ,RESEARCH ,SCIENTIFIC observation ,METASTASIS ,RETROSPECTIVE studies ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,PROGRESSION-free survival ,LONGITUDINAL method - Abstract
The optimal therapeutic options, adding locoregional therapy (LRT) to systemic therapy (ST) or not, for patients with oligometastatic breast cancer (OMBC) have not been fully elucidated. Hence, we designed a retrospective observational study which enrolled patients with measurable extracranial OMBC having less than 5 metastatic lesions not necessarily in the same organ. We retrospectively reviewed a total of 199 patients diagnosed with extracranial OMBC, including 28 receiving ST followed by LRT (ST to LRT group), 44 receiving LRT followed by ST (LRT to ST group), and 127 receiving ST alone (ST alone group). After a median follow-up of 28.7 months, patients receiving both ST and LRT had a significantly better prognosis than those receiving ST alone: the median progression-free survival (PFS) was 16.3, 14.0, and 9.3 months (P < 0.001) and the median overall survival (OS) was 39.8, 70.5, and 26.7 months (P < 0.001) in the ST to LRT, LRT to ST, and ST alone groups, respectively. Sequence of ST and LRT had no significant impact on survival among patients receiving both. Further exploratory analysis identified ST plus LRT as an independent predictor for longer PFS. In conclusion, we demonstrated that adding LRT to ST was associated with survival benefits for patients with OMBC, and further prospective studies were warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
- Author
-
Zhang, Kai, Hong, Ruoxi, Xu, Fei, Xia, Wen, Kaping, Lee, Qin, Ge, Zheng, Qiufan, Lu, Qianyi, Shi, Yan Xia, Yuan, Zhong Yu, and Wang, Shusen
- Subjects
ESR1 mutations ,Review ,breast carcinoma ,ctDNA ,cfDNA ,meta analysis - Abstract
Background The clinical implication of plasma ESR1 mutations in the estrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who had progressed after prior aromatase inhibitor (AI)-based therapy remains controversial. We conducted the first meta-analysis to investigate the prognostic significance and predictive role of plasma ESR1 mutations in MBC patients with prior exposure to AI therapy. Materials and methods We searched PubMed, Embase, and Cochrane Library databases for eligible studies. Meta-analysis was conducted to calculate combined hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Subgroup and sensitivity analyses were also performed. Results This study enrolled a total of 1,530 patients with ER-positive MBC cases from six articles, including 429 ESR1 mutation carriers (28.04%). Meta-analysis demonstrated that plasma ESR1 mutation carriers had significantly worse PFS (HR: 1.40, 95% CI: 1.17–1.66; P
- Published
- 2018
17. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
- Author
-
Wang, Liye, Zhai, Qinglian, Lu, Qianyi, Lee, Kaping, Zheng, Qiufan, Hong, Ruoxi, and Wang, Shusen
- Subjects
TRIPLE-negative breast cancer ,CHINESE people ,CANCER patients ,CANCER relapse ,NUCLEOTIDE sequencing ,GENE rearrangement - Abstract
Triple-negative breast cancer (TNBC) represents about 19% of all breast cancer cases in the Chinese population. Lack of targeted therapy contributes to the poorer outcomes compared with other breast cancer subtypes. Comprehensive genomic profiling helps to explore the clinically relevant genomic alterations (CRGAs) and potential therapeutic targets in very-early-relapsed TNBC patients. Formalin-fixed paraffin-embedded (FFPE) tumour tissue specimens from 23 patients with very-early-relapsed TNBC and 13 patients with disease-free survival (DFS) more than 36 months were tested by FoundationOne CDx (F1CDx) in 324 genes and select gene rearrangements, along with genomic signatures including microsatellite instability (MSI) and tumour mutational burden (TMB). In total, 137 CRGAs were detected in the 23 very-early-relapsed TNBC patients, averaging six alterations per sample. The mean TMB was 4 Muts/Mb, which was higher than that in non-recurrence patients, and is statistically significant. The top-ranked altered genes were TP53 (83%), PTEN (35%), RB1 (30%), PIK3CA (26%) and BRCA1 (22%). RB1 mutation carriers had shorter DFS. Notably, 100% of these patients had at least one CRGA, and 87% of patients had at least one actionable alteration. In pathway analysis, patients who carried a mutation in the cell cycle pathway were more likely to experience very early recurrence. Strikingly, we detected one patient with ERBB2 amplification and one patient with ERBB2 exon20 insertion, both of which were missed by immunohistochemistry (IHC). We also detected novel alterations of ROS1–EPHA7 fusion for the first time, which has not been reported in breast cancer before. The comprehensive genomic profiling can identify novel treatment targets and address the limited options in TNBC patients. Therefore, incorporating F1CDx into TNBC may shed light on novel therapeutic opportunities for these very-early-relapsed TNBC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer.
- Author
-
Zhou, Danyang, Jiang, Kuikui, Hong, Ruoxi, Lu, Qianyi, Xia, Wen, Li, Mei, Zheng, Chengyou, Zheng, Qiufan, Xu, Fei, and Wang, Shusen
- Subjects
PROGNOSIS ,BREAST cancer ,BIOMARKERS ,KI-67 antigen ,SURVIVAL analysis (Biometry) - Abstract
Background: To assess the distribution characteristics and the prognostic value of immune infiltration in female oligometastatic breast cancer patients. Methods: We retrospectively analyzed the clinicopathological data of oligometastatic breast cancer (OMBC) patients diagnosed between June 2000 and January 2020. Immune markers were quantified by immunohistochemistry on FFPE tissues in paired normal breast tissues, primary breast cancers and oligometastatic lesions. Survival analyses were performed using the Kaplan-Meier curves and Cox-proportional hazards model. Results: A total of 95 female OMBC patients visited Sun Yat-sen University Cancer Center between June 2000 and January 2020, and 33 of them had matched normal breast tissues, primary cancers and oligometastatic lesions and were reviewed in immune infiltration analysis. CD8 of primary tumors had a higher expression than that in matched normal tissues. The expressions of CD8 and FOXP3 were higher in the primary sites than that in the oligometastatic lesions. CD3, CD4 and CD8 were significantly lower in the intratumoral regions than that in the peritumoral regions both in primary and oligometastatic lesions. Notably, the high percentage of CD3 in the intratumoral oligometastatic lesions predicted the longer PFS and OS, and higher CD4 in the same lesions also predicted a better OS. There was obviously positive correlation between CD4/CD3 and Ki-67 in primary cancers and negative correlation between CD4/CD3 and ER in oligometastatic sites. Conclusion: We explored immune distribution and evolution in time and space in OMBC to provide new understandings for biological behaviors of this disease and further divided patients in different prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy.
- Author
-
Xu, Fei, Zheng, Qiufan, Xia, Wen, Ouyang, Quchang, Pang, Danmei, Yuan, Zhongyu, Shi, Yanxia, Peng, Roujun, Lu, Qianyi, and Wang, Shusen
- Subjects
DRUG efficacy ,DISEASE progression ,INJECTIONS ,CLINICAL trials ,CONFIDENCE intervals ,ANTINEOPLASTIC agents ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,POSTMENOPAUSE ,SURVIVAL analysis (Biometry) ,ODDS ratio ,HORMONE receptor positive breast cancer ,PATIENT safety ,EVALUATION - Abstract
Lessons Learned: Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression‐free survival of 16.1 months in patients who achieved objective responses or disease control after first‐line chemotherapy.Adverse events with fulvestrant maintenance therapy were consistent with the known safety profile of the drug. Background: Evidence for maintenance hormonal therapy after chemotherapy for estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer is scarce. This study aimed to evaluate the efficacy of fulvestrant 500 mg maintenance therapy in patients after first‐line chemotherapy. Methods: We enrolled postmenopausal women with ER‐positive/HER2‐negative advanced breast cancer who attained tumor responses or disease control with four to eight cycles of chemotherapy as first‐line treatment. Fulvestrant 500 mg was injected on days 1, 15, and 29 and every 28 (±3) days thereafter. The primary endpoint was the clinical benefit rate (CBR); the secondary endpoints included the objective response rate (ORR), progression‐free survival (PFS), and safety. Results: We included 58 patients; the median follow‐up duration was 32.6 months. The CBR since commencing fulvestrant maintenance therapy was 76% (95% confidence interval [CI], 63%–86%), and ORR was 14% (95% CI, 6%–25%); eight patients achieved partial response. The median PFS for fulvestrant maintenance therapy was 16.1 months (95% CI, 10.3–21.0 months). Thirty‐nine patients (67%) reported at least one adverse event, of which most were grade 1/2, whereas three patients (5%) reported grade 3 adverse events. Conclusion: Fulvestrant 500 mg is a feasible and promising hormonal maintenance strategy in patients with ER‐positive/HER2‐negative advanced breast cancer who have no disease progression after first‐line chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study.
- Author
-
Xu, Fei, Lee, Kaping, Xia, Wen, Liao, Hai, Lu, Qianyi, Zhang, Jingmin, Yuan, Huimin, Zhang, Kai, Zheng, Qiufan, Qin, Ge, Zhai, Qinglian, Hong, Ruoxi, Jiang, Kuikui, Li, Yuan, and Wang, Shusen
- Subjects
ACADEMIC medical centers ,ANTINEOPLASTIC agents ,BLOOD plasma ,BREAST tumors ,CANCER patients ,CLINICAL trials ,INGESTION ,LIQUID chromatography ,METASTASIS ,PROTEIN-tyrosine kinase inhibitors ,DESCRIPTIVE statistics ,PHARMACODYNAMICS - Abstract
Lessons Learned: Administration of lapatinib with food significantly increased its plasma concentration in Chinese patients with metastatic breast cancer.There were no serious adverse events during the study and no significant differences in lapatinib‐related adverse events between the fasted and fed states. Background: Lapatinib, a small molecular reversible dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth receptor 2 (HER2), was approved for use in combination with capecitabine to treat metastatic HER2‐positive breast cancer. Administration of lapatinib in the fasted state was recommended; however, our preliminary phase II trial data showed that administration of lapatinib with food increased its concentration. Methods: This study was a single‐center, open‐label, and prospective self‐controlled clinical study. Ten Chinese patients with metastatic breast cancer were enrolled from June 2017 to April 2018. They were required to receive lapatinib plus physician's choice of chemotherapy. Patients were required to take lapatinib orally on an empty stomach continually for 10 days, and then take lapatinib with food continually for the next 10 days. Plasma concentration was measured by liquid chromatography on the 9th and 10th day of each state. Results: Area under the concentration‐time curve (AUC) of the fasted state and the fed state was 21.23 ± 8.91 mg*h/L (coefficient of variation (CV)% 42%) and 60.60 ± 16.64 mg*h/L (CV% 27%), respectively. The mean plasma concentration in the fasted state was 0.88 ± 0.39 mg/L (CV% 45%), and that in the fed state was 2.53 ± 0.77 mg/L (CV% 30%). Compared with taking lapatinib on an empty stomach, receiving lapatinib with food significantly increased the plasma concentration of lapatinib (Wilcoxon match‐paired test, p =.005). In addition, there were no serious adverse events during the study or significant difference in lapatinib‐related adverse events between the two states. Conclusion: Our study shows that receiving lapatinib with food can increase its plasma concentration with no significantly increased drug‐related toxicity. We suggest that a larger‐sample‐size clinical trial is needed to fully understand the effect of administration of lapatinib with food. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center.
- Author
-
Lu, Qianyi, Lee, Kaping, Xu, Fei, Xia, Wen, Zheng, Qiufan, Hong, Ruoxi, Jiang, Kuikui, Zhai, Qinglian, Li, Yuan, Shi, Yanxia, Yuan, Zhongyu, and Wang, Shusen
- Published
- 2020
- Full Text
- View/download PDF
22. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib
- Author
-
Zheng, Qiufan, Fang, Wenfeng, Huang, Yihua, Gan, Jiadi, and Zhang, Li
- Published
- 2020
- Full Text
- View/download PDF
23. Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy
- Author
-
Fang, Wenfeng, Huang, Yihua, Gan, Jiadi, Zheng, Qiufan, and Zhang, Li
- Published
- 2020
- Full Text
- View/download PDF
24. Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer
- Author
-
Zheng, Qiufan, Xu, Fei, Nie, Man, Xia, Wen, Qin, Tao, Qin, Ge, An, Xin, Xue, Cong, Peng, Roujun, Yuan, Zhongyu, Shi, Yanxia, and Wang, Shusen
- Subjects
Adult ,Aged, 80 and over ,Selective Estrogen Receptor Modulators ,nutritional and metabolic diseases ,Observational Study ,Breast Neoplasms ,Middle Aged ,Prognosis ,digestive system ,Survival Analysis ,digestive system diseases ,Tamoxifen ,Non-alcoholic Fatty Liver Disease ,Humans ,Regression Analysis ,Female ,Toremifene ,Research Article ,Aged ,Retrospective Studies ,Ultrasonography - Abstract
Selective estrogen receptor modulator (SERM)-associated nonalcoholic fatty liver disease (NAFLD) might be related to treatment efficacy in patients with breast cancer because of circulating estrogen antagonism. The aim of the study was to investigate the relationship between NAFLD and survival outcomes in patients with breast cancer who were treated with tamoxifen or toremifene. This single-center, retrospective, cohort study included 785 eligible patients who received tamoxifen or toremifene, after curative resection for breast cancer, at the Sun Yat-sen University Cancer Center between January 2005 and December 2009. Data were extracted from patient medical records. All patients underwent abdominal ultrasonography, at least once, at baseline and at the annual follow-up. Patients who were diagnosed with NAFLD on ultrasonography were classified into the NAFLD or the non-NAFLD arm at the 3-year follow-up visit. Univariate and multivariate Cox regression analyses were conducted to evaluate any associations between NAFLD and disease-free survival (DFS) or overall survival (OS). One hundred fifty-eight patients were diagnosed with NAFLD. Patients who developed NAFLD had better DFS and OS compared with those who did not. Univariate analyses revealed that the 5-year DFS rates were 91.56% and 85.01% for the NAFLD and non-NAFLD arms, respectively (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.37–0.96; log-rank P = 0.032). The 5-year OS rates were 96.64% and 93.31% for the NAFLD and non-NAFLD arms, respectively (HR, 0.39; 95% CI, 0.16–0.99; log-rank P = 0.039). Multivariate analysis revealed that NAFLD was an independent prognostic factor for DFS, improving the DFS rate by 41% compared with that in the non-NAFLD arm (HR, 0.59; 95% CI, 0.36–0.96; P = 0.033). SERM-associated NAFLD was independently associated with improved DFS and might be useful for predicting treatment responses in breast cancer patients treated with SERMs.
- Published
- 2015
25. Clinical value of circulating <em>ESR1</em> mutations for patients with metastatic breast cancer: a meta-analysis.
- Author
-
Zhang, Kai, Hong, Ruoxi, Xu, Fei, Xia, Wen, Kaping, Lee, Qin, Ge, Zheng, Qiufan, Lu, Qianyi, Shi, Yan Xia, Yuan, Zhong yu, and Wang, Shusen
- Subjects
ESTROGEN receptors ,METASTATIC breast cancer ,GENETICS of breast cancer ,BREAST cancer treatment ,META-analysis - Abstract
Background: The clinical implication of plasma ESR1 mutations in the estrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who had progressed after prior aromatase inhibitor (AI)-based therapy remains controversial. We conducted the first meta-analysis to investigate the prognostic significance and predictive role of plasma ESR1 mutations in MBC patients with prior exposure to AI therapy. Materials and methods: We searched PubMed, Embase, and Cochrane Library databases for eligible studies. Meta-analysis was conducted to calculate combined hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Subgroup and sensitivity analyses were also performed. Results: This study enrolled a total of 1,530 patients with ER-positive MBC cases from six articles, including 429 ESR1 mutation carriers (28.04%). Meta-analysis demonstrated that plasma ESR1 mutation carriers had significantly worse PFS (HR: 1.40, 95% CI: 1.17–1.66; P [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer: A Retrospective Cohort Analysis.
- Author
-
Qiufan Zheng, Fei Xu, Man Nie, Wen Xia, Tao Qin, Ge Qin, Xin An, Cong Xue, Roujun Peng, Zhongyu Yuan, Yanxia Shi, Shusen Wang, Zheng, Qiufan, Xu, Fei, Nie, Man, Xia, Wen, Qin, Tao, Qin, Ge, An, Xin, and Xue, Cong
- Published
- 2015
- Full Text
- View/download PDF
27. Cover Image: Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center.
- Author
-
Lu, Qianyi, Lee, Kaping, Xu, Fei, Xia, Wen, Zheng, Qiufan, Hong, Ruoxi, Jiang, Kuikui, Zhai, Qinglian, Li, Yuan, Shi, Yanxia, Yuan, Zhongyu, and Wang, Shusen
- Published
- 2020
- Full Text
- View/download PDF
28. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
- Author
-
Zhang, Yaxiong, Chang, Lianpeng, Yang, Yunpeng, Fang, Wenfeng, Guan, Yanfang, Wu, Aiwei, Hong, Shaodong, Zhou, Huaqiang, Chen, Gang, Chen, Xi, Zhao, Shen, Zheng, Qiufan, Pan, Hui, Zhang, Lanjun, Long, Hao, Yang, Haoxian, Wang, Xin, Wen, Zhesheng, Wang, Junye, and Yang, Hong
- Subjects
NON-small-cell lung carcinoma ,BLOOD cells - Abstract
High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations of single-region tTMB, multi-region tTMB and bTMB remain to be determined. Moreover, whether intratumor heterogeneity (ITH) has impact on TMB should be clarified. We collected multi-region tumor tissues with matched blood from 32 operative NSCLC and evaluated single-region tTMB, multi-region tTMB and bTMB through a 1021-gene panel sequencing. TMB of > 9 mutations/Mb was classified as high. Besides, we used tTMB fold-change to evaluate the influence of the enrolled region number on tTMB. We found both of single-region tTMB and bTMB showed strong correlations with multi-region tTMB, while the former correlated better (Pearson r = 0.94, P = 2E-84; Pearson r = 0.47, P = 0.0067). It showed extremely high specificity (100%) but low sensitivity (43%) when using bTMB to define TMB-high patients, while most false-negative predictions were in early-stage patients. Compared to single region, we found significantly enhanced tTMB fold-change if taking multi-regions for consideration. However, it showed insignificant tTMB fold-change increase if the included regions' number more than three. Moreover, ITH-high patients had significantly higher tTMB fold-change compared with ITH-low patients (2.32 vs. 1.02, P = 8.879e-05). The conversion rate of tTMB level (tTMB-low to tTMB-high) was numerically higher in ITH-high group than that in ITH-low group (16.67% vs. 3.84%). In summary, single-region tTMB has stronger correlation with multi-region tTMB compared with bTMB. ITH has an impact on tTMB, especially in high-level ITH patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
- Author
-
Zhang, Kai, Hong, Ruoxi, Kaping, Lee, Xu, Fei, Xia, Wen, Qin, Ge, Zheng, Qiufan, Lu, Qianyi, Zhai, Qinglian, Shi, Yanxia, Yuan, Zhongyu, Deng, Wuguo, Chen, Miao, and Wang, Shusen
- Subjects
- *
EPIDERMAL growth factor receptors , *BREAST cancer , *KINASE inhibitors , *CELL cycle , *EPIDERMAL growth factor - Abstract
Human epidermal growth factor receptor 2 (HER2) is amplified in about 20% breast cancers. Treat of HER2 positive breast cancers has been greatly promoted in last few years, but the accompany HER2 blockade has hindered the therapeutic effect. Pyrotinib is a pan-HER kinase inhibitor that suppresses signaling through the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. Palbociclib is a CDK4/6 inhibitor that inhibits cell cycle progression and cancer cell proliferation in ER+ breast cancers. We hypothesized that the combination of pan-HER kinase inhibitors and CDK4/6 inhibitors would show synergistic antitumor activity in vivo in vitro. Our data show that a combination of palbociclib and pyrotinib was highly synergistic in inhibiting cancer proliferation and colony formation. The combined treatment also induced significant decreases in pAKT and pHER3 activation, induced G0-G1 cell cycle arrest, and increased rates of apoptosis. In the xenograft model, the combination treatment demonstrated greater antitumor activity than either agent alone, with no apparent increase in toxicity. Our results offer a preclinical rationale clinical investigation of the effectiveness of a combination treatment of palbociclib with pyrotinib for breast cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. Construction of immune score and its prognostic value in invasive lobular carcinoma of the breast using computational pathology analysis.
- Author
-
Wang L, Sun P, Xu F, Zheng Q, Jiang K, Hong R, and Wang S
- Subjects
- Humans, Female, Prognosis, Middle Aged, Forkhead Transcription Factors metabolism, Antigens, CD metabolism, Computational Biology methods, Disease-Free Survival, Antigens, Differentiation, Myelomonocytic metabolism, Neoplasm Staging, Aged, CD68 Molecule, Breast Neoplasms pathology, Breast Neoplasms mortality, Breast Neoplasms immunology, Breast Neoplasms metabolism, Carcinoma, Lobular pathology, Carcinoma, Lobular mortality, Carcinoma, Lobular immunology, Carcinoma, Lobular metabolism, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Biomarkers, Tumor, Tumor Microenvironment immunology
- Abstract
Background: Previous studies have shown that high level of TILs in invasive lobular carcinoma (ILC) is associated with poor prognosis, contrary to that in TNBC and HER2-positive breast cancer., Methods: The densities of six immune cell markers and three immune checkpoints in the ILC microenvironment were detected by computational pathology analysis. Then, the LASSO cox regression model was used to construct an immune score (IS) and further evaluate its prognostic value., Results: In our ILC cohort, the low density of CD4, CD8, CD20, CD56, CD68, FOXP3, PD-1, and PD-L1 had significantly longer disease-free survival (DFS) and overall survival (OS); however, the low density of CTLA-4 was associated with shorter DFS and OS. Based on this, an IS was constructed, and patients with low-IS had significantly prolonged DFS (p < 0.0001) and OS (p < 0.0001). Multivariate analysis revealed that IS was an independent prognostic indicator for DFS and OS. Further analysis showed that IS may increase the prognostic value of TNM stage. We further explored the prognostic role of CD68 and FOXP3 in the transcriptional level and the corresponding ISm in the METABRIC dataset, and found that low proportion of CD68 and FOXP3 and their ISm were associated with longer OS, and ISm was also an independent prognostic factor for OS., Conclusion: IS was a promising biomarker to distinguish the prognosis in ILC patients., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
31. Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer.
- Author
-
Luo H, Hong R, Xu Y, Zheng Q, Xia W, Lu Q, Jiang K, Xu F, Chen M, Shi D, Deng W, and Wang S
- Abstract
Background: Triple-negative breast cancer (TNBC) is a highly heterogeneous disease and the current prognostic system cannot meet the clinical need. Interactions between immune responsiveness and tumor cells plays a key role in the progression of TNBC and macrophages are vital component of immune cells. A prognostic model based on macrophages may have great accuracy and clinical utility., Methods: For model development, we screened early stage (without metastasis) TNBC patients from The Cancer Genome Atlas (TCGA) database. We extracted messenger RNA (mRNA) expression data and clinical data including age, race, tumor size, lymph node status and tumor stage. The follow up time and vital status were also retrieved for overall survival calculation. Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was used to calculate the immune cell composition of each sample. Weighted gene co-expression network analysis (WGCNA) was used to identify M1-like macrophage-related genes. Combining least absolute shrinkage and selection operator (LASSO) with multivariate Cox regression, the M1-like macrophage polarization-related prognostic index (MRPI) was established. We obtained TNBC patients in Gene Expression Omnibus (GEO) database through PAM50 method and retrieved the mRNA expression data and survival data. The Harrell's concordance index (CI), the area under the receiver operating characteristic (ROC) curves (AUCs) and the calibration curve were used to evaluate the developed model., Results: We obtained 166 early TNBC cases and 113 normal tissue cases for model building, along with 76 samples from GSE58812 cohort for model validation. CIBERSORT analysis suggested obvious infiltration of macrophages, especially M1-like macrophages in early TNBC. Four genes were eventually identified for the construction of MPRI in the training set. The AUCs at 2 years, 3 years, and 5 years in the training cohort were 0.855, 0.881 and 0.893, respectively; and the AUCs at 2 years, 3 years, and 5 years in the validation cohort were 0.887, 0.792 and 0.722, respectively. Calibration curves indicated good predictive ability and high consistency of our model., Conclusions: MRPI is a promising biomarker for predicting the prognosis of early-stage TNBC, which may indicate personalized treatment and follow-up strategies and thus may improve the prognosis., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-23-6/coif). The authors have no conflicts of interest to declare., (2023 Gland Surgery. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
32. Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer.
- Author
-
Zhang K, Jiang K, Hong R, Xu F, Xia W, Qin G, Lee K, Zheng Q, Lu Q, Zhai Q, and Wang S
- Abstract
Background: Tamoxifen resistance in breast cancer is an unsolved problem in clinical practice. The aim of this study was to determine the potential mechanisms of tamoxifen resistance through bioinformatics analysis., Methods: Gene expression profiles of tamoxifen-resistant MCF-7/TR and MCF-7 cells were acquired from the Gene Expression Omnibus dataset GSE26459, and differentially expressed genes (DEGs) were detected with R software. We conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses using Database for Annotation, Visualization and Integrated Discovery. A protein-protein interaction (PPI) network was generated, and we analyzed hub genes in the network with the Search Tool for the Retrieval of Interacting Genes database. Finally, we used siRNAs to silence the target genes and conducted the MTS assay., Results: We identified 865 DEGs, 399 of which were upregulated. GO analysis indicated that most genes are related to telomere organization, extracellular exosomes, and binding-related items for protein heterodimerization. PPI network construction revealed that the top 10 hub genes- ACLY, HSPD1, PFAS, GART, TXN, HSPH1, HSPE1, IRAS, TRAP1 , and ATIC -might be associated with tamoxifen resistance. Consistently, RT-qPCR analysis indicated that the expression of these 10 genes was increased in MCF-7/TR cells comparing with MCF-7 cells. Four hub genes ( TXN, HSPD1, HSPH1 and ATIC ) were related to overall survival in patients who accepted tamoxifen. In addition, knockdown of HSPH1 by siRNA may lead to reduced growth of MCF-7/TR cell with a trend close to significance ( P = 0.07), indicating that upregulation of HSPH1 may play a role in tamoxifen resistance., Conclusion: This study revealed a number of critical hub genes that might serve as therapeutic targets in breast cancer resistant to tamoxifen and provided potential directions for uncovering the mechanisms of tamoxifen resistance., Competing Interests: The authors declare that they have no competing interests., (© 2020 Zhang et al.)
- Published
- 2020
- Full Text
- View/download PDF
33. EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients.
- Author
-
Zheng Q, Huang Y, Zhao H, Yang Y, Hong S, Hou X, Zhao Y, Ma Y, Zhou T, Zhang Y, Fang W, and Zhang L
- Abstract
Background: Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor (TKI) with robust activity in advanced EGFR -mutant non-small cell lung cancer (NSCLC), including those with T790M resistance mutation. However, a broad interpatient variability was observed. This study aimed to evaluate whether EGFR -mutant genotypes affect the clinical outcomes and resistance mechanisms in T790M-positive NSCLC patients receiving osimertinib therapy., Methods: All NSCLC patients treated with osimertinib in our institute were screened. We included those with known EGFR -mutant genotypes and T790M positivity. Clinical outcomes including objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS), were evaluated and compared between different EGFR genotypes. Patients with next-generation sequencing testing or tumor rebiopsy after osimertinib treatment were analyzed for resistance mechanisms., Results: ORR, CBR, PFS, and OS were all non-significantly different among patients harboring EGFR exon 19 deletion (19Del, n=136), L858R (n=93), and uncommon mutations (n=6). However, a subset of tumors with deletion starting at E746 (ΔE746, n=98), but not non-ΔE746 tumors (n=38), had better clinical outcomes than L858R tumors (n=93). Frequencies of T790M loss and C797S acquisition after osimertinib treatment were similar between 19Del (n=56) and L858R tumors (n=33). However, compared with L858R tumors (n=33), those with 19Del ΔE746 subtype (n=40) had a higher whereas non-ΔE746 subtype (n=16) had a similar frequency of acquired C797S mutation. Combined analysis of our cohort and public cohort confirmed these findings., Conclusions: Our findings indicate that the EGFR 19Del subtypes affect the clinical outcomes and resistance mechanisms to osimertinib in T790M-positive patients. Identifying patients with relatively worse treatment outcomes may be informative for establishing new therapies for these patients., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2020.03.35). The authors have no conflicts of interest to declare., (2020 Translational Lung Cancer Research. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
34. Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy.
- Author
-
Jiang K, Xia W, Hong R, Xu F, Zheng Q, Lu Q, Lee K, Li Y, Zhai Q, Shi Y, Yuan Z, and Wang S
- Abstract
Background: The role of local treatment for liver oligometastases in breast cancer patients has been controversial. The aim of the study was to evaluate the prognostic factors for overall survival (OS) and progression-free survival (PFS) after hepatic local treatment and to explore appropriate therapy strategy in breast cancer patients with liver oligometastases., Methods: A cohort of 91 patients with oligometastatic liver lesions identified from around 34,000 breast cancer patients between 2002 and 2018 were retrospectively reviewed. We collected and analyzed their clinicopathologic and outcome data., Results: With a median follow up of 20.6 months [standard deviations (SD): 35.4], median OS and median PFS were 75.1 months [95% confidence interval (CI): 14.3-135.9 months] and 7.4 months (95% CI: 4.4-10.4 months), respectively. N3 stage, triple-negative breast cancer (TNBC) subtype, progressive disease (PD) after preoperative systemic therapy and older age of operation were associated with worse OS and PFS while postoperative systemic therapy alone, preoperative [partial response (PR)/stable disease (SD)] combined with postoperative systemic therapy indicated improved OS and PFS by univariate analysis. On multivariate analysis, N3 stage [hazard ratios (HR) 23.567; 95% CI: 1.751-317.277; P=0.017] and TNBC subtype (HR 10.758; 95% CI: 1.120-103.301; P=0.040) were related to worse OS. Likewise, N3 stage (HR 3.324; 95% CI 1.604-6.890; P=0.001) and TNBC subtype (HR 3.134; 95% CI: 1.015-9.674; P=0.047) remained associated with worse PFS. The postoperative mortality and morbidity were 0% and 1.099%, respectively., Conclusions: In well-selected patients, local treatment of breast cancer liver oligometastases is safe and achieves relatively long OS, except patients with advanced N stage or aggressive subtype. Postoperative systemic treatment and effective preoperative systemic therapy combined with postoperative systemic therapy are the recommended treatment strategies., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.12.93). The authors have no conflicts of interest to declare., (2020 Translational Cancer Research. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
35. Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer.
- Author
-
Qin T, Zeng YD, Lu Q, Zhang X, Qin GE, Zheng Q, Xu F, Peng R, Yuan Z, and Wang S
- Subjects
- Adult, Biomarkers, Tumor, Breast Neoplasms therapy, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Middle Aged, Nomograms, Prognosis, Retrospective Studies, Young Adult, Breast Neoplasms mortality, Breast Neoplasms pathology, Lymph Nodes pathology, Premenopause
- Abstract
Aim: The aim of this study was to assess the prognostic value of lymph node ratio (LNR) in premenopausal patients with luminal breast carcinoma., Materials and Methods: A total of 885 female patients who presented with axillary lymph node-positive luminal breast cancer between 2000 and 2009 were investigated. Using X-tile, we classified patients into low-, intermediate- and high-risk groups based on LNR. The Kaplan-Meier method was used to determine cumulative survival curves. Cox proportional hazards analyses were used to identify the factors that contributed to disease-free (DFS) and overall (OS) survival., Results: The median age of patients was 42 years (range=21-58 years). A training set of 295 patients and a validation set of 590 patients were used to determine the optimal LNR cut-off points (0.20 and 0.63). DFS was 87.7%, 77.4% and 53.9% (p<0.001) and OS was 91.5%, 76.7% and 50.9% (p<0.0001) for the low- (≤0.20), intermediate- (0.21-0.63) and high-risk (>0.63) groups, respectively. The 10-year DFS and OS rates were significantly longer in the low-risk group than in the high-risk group. Nomogram analysis demonstrated that LNR contributed more compared to nodal stage in predicting both DFS and OS., Conclusion: We conclude that LNR strongly predicts prognosis in premenopausal patients with lymph node-positive luminal breast cancer., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
36. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.
- Author
-
Qin G, Xu F, Qin T, Zheng Q, Shi D, Xia W, Tian Y, Tang Y, Wang J, Xiao X, Deng W, and Wang S
- Subjects
- Animals, Binding Sites, Breast Neoplasms enzymology, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Line, Tumor, Cyclooxygenase 2 genetics, Dinoprostone metabolism, Female, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms enzymology, Lung Neoplasms genetics, Lung Neoplasms secondary, Mice, Nude, Phosphorylation, Promoter Regions, Genetic, Proto-Oncogene Proteins c-jun genetics, Retinoblastoma Protein metabolism, Transfection, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Breast Neoplasms drug therapy, Cell Movement drug effects, Cyclooxygenase 2 metabolism, Cyclooxygenase 2 Inhibitors pharmacology, Epithelial-Mesenchymal Transition drug effects, Lung Neoplasms prevention & control, Piperazines pharmacology, Proto-Oncogene Proteins c-jun metabolism, Pyridines pharmacology, Signal Transduction drug effects
- Abstract
Palbociclib, a highly selective CDK4/6 inhibitor, has been shown to be a novel anti-tumor agent that suppresses breast cancer cell proliferation. However, its anti-metastasis activity remains controversial. In the present study, we evaluated whether palbociclib prevented breast cancer cell metastasis and revealed its regulatory mechanism. We found that palbociclib inhibited migration and invasion in the breast cancer cells MDA-MB-231 and T47D. The epithelial-mesenchymal transition (EMT) markers, vimentin and Snail, were down-regulated with palbociclib treatment. Moreover, we revealed that this inhibition was mediated by the c-Jun/COX-2 pathway. COX-2 was decreased after palbociclib treatment. The production of PGE2 was also reduced along with COX-2. Additionally, our data showed that c-Jun, a crucial transcriptional regulator of COX-2, was down-regulated by palbociclib. We found that palbociclib weakened the COX-2 promoter binding activity of c-Jun and prevented its translocation from the cytoplasm to cell nuclei. Bioluminescence imaging and tail intravenous injection were used to evaluate the anti-metastasis effect of palbociclib in vivo. The data demonstrated that palbociclib reduced breast cancer metastasis to the lung. These results therefore demonstrated that the anti-metastasis activity of palbociclib is mediated via the c-Jun/COX-2 signaling pathway by inhibiting EMT in breast cancer cells.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.